The Peptide NewsroomPeptide research, industry and supply-chain headlines

FDA's Peptide Compounding Shakeup Blurs Drug and Supplement Lines, and Legitimate Brands Are Exposed

Topic card: fda

A feature in New Hope Network reports that the collapsing boundary between peptide drugs, compounded prescriptions and dietary supplements is the biggest regulatory moment the supplement industry has faced in decades. Industry advisor Loren Israelsen, who helped craft DSHEA in 1994 and watched the ephedra ban and the CBD collapse, told the outlet the peptide moment is "pacing to be the largest" and also "the foggiest."

The confusion starts with the word itself. "Peptide" now covers FDA-approved drugs such as the GLP-1s, patient-specific compounded medications, unapproved gray-market injectables like BPC-157 and TB-500, and decades-old supplement ingredients including collagen and milk-derived peptides.

How the rules moved

In April, 12 gray-market peptides came off the FDA's do-not-compound list, leaving them in what the piece calls regulatory purgatory. Three months later the agency's Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides, including BPC-157 and TB-500, for compounding access, going against the recommendations of FDA's own scientists.

In October, FDA and the federal health department announced steps to revise compounding policy for peptide drugs. Legal experts quoted in the article expect a contested process, with comment periods and litigation, following the pattern set by the GLP-1 shortage determinations in 2022 and 2023.

Research chemicals with a Supplement Facts panel

The sharper problem is products sold as supplements that contain injectable research peptides. Michael Levin of Health Business Strategies is blunt about it: "It's illegal. Hard stop," he says, describing brands buying research chemicals that are unlawful in a dietary supplement.

Ashish Talati of Talati Law Firm makes the same point: calling an unapproved drug a supplement, a research chemical or RUO does not change what it is. Oliver Catlin of BSCG warns the harm runs past reputation into category collapse, since every exception chips at what the word supplement is supposed to mean.

Who actually loses

The weight management shelf is the cautionary tale. SPINS data cited in the piece shows weight-loss supplements declining at a low-double-digit rate, on top of an 11.9% drop reported at Expo West 2025, while 21% of households now include a GLP-1 user and 80% of those users take a companion supplement.

Bottom line

Israelsen's suggested route is the helper role rather than the headline ingredient, and Jacques argues a rising tide lifts all peptide categories. Neither outcome is settled until FDA says what its revised compounding policy actually is.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: fda, supply

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Sermorelin Goes Mainstream on Telehealth, but the Dosing and Efficacy Data Are Missing

Sermorelin, a peptide that stimulates growth-hormone release, is now sold nationally through Hims and Hers as part of its compounded Peptides+ platform. Neither the company nor the outside experts quoted can point to human outcome trials or an established dose.

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.

Ingredient Supplier Kemin Puts GLP-1 Companion Nutrition at the Center of Its 2027 Outlook

At SupplySide Global, ingredient developer Kemin outlined a 2027 wellness outlook built on GLP-1 companion nutrition, gut health, and positive aging, with FloraGLO Lutein repositioned toward cognition. No trial data or outcome figures appear anywhere in the coverage, which makes this a supplier forecast rather than new evidence.